LAUNCHES, PROMOTIONS, MERCHANDISING, EVENTS AND OTHER THINGS TO KEEP YOU IN THE KNOW.
STUDY FINDS CONSENSUS IN SCLERAL LENS RXES
A reasonable degree of consensus exists among eyecare practitioners in prescribing scleral lenses and manageing patients, concluded the SCOPE Study in the April 6 issue of Eye & Contact Lens. In SCOPE, which stands for Scleral Lenses in Current Ophthalmic Practice: An Evaluation, the study group administered an online survey asking ECPs about prescription and management practices. Of 663 respondents, 65% prescribed lenses that were 15 to 17mm in diameter, 18% prescribed lenses that were smaller than 15mm, and 17% prescribed lenses that were larger than 18mm. Also, 651 respondents said that average daily wearing time was 11.8 hours, and 475 of those individuals (73%) recommended midday removal. Most respondents recommended nonpreserved saline to fill the bowl of the lens before application and a hydrogen peroxide-based disinfection system.
NASAL STIMULATION FOR DRY EYE PATIENTS
Allergan plc has been granted marketing authorization from the U.S. Food and Drug Administration (FDA) for True-Tear Intranasal Tear Neurostimulator, which temporarily increases tear production during neurostimulation in adult patients. True-Tear is a handheld stimulator with daily disposable tips that are inserted into the nasal cavity to induce the production of tears. In clinical trials, True-Tear resulted in increased tear production upon stimulation of the nasal cavity. Allergan.com
COVERAGE ASSISTANCE FOR CROSS-LINKING
Avedro, Inc., will launch a comprehensive effort to help patients get coverage for Photrexa Viscous (riboflavin 5’-phosphate in 20% dextran solution), Photrexa (riboflavin 5’-phosphate dextran solution) and the KXL System used in corneal cross-linking for the treatment of progressive keratoconus and corneal ectasia following refractive surgery. The initiative, known as the Avedro Reimbursement Customer Hub (ARCH) Program, will offer the following: a reimbursement support service with a hotline for questions and resources to assist with the commercial payer appeals process; a patient assistance program in which financially eligible, uninsured patients can receive Photrexa Viscous and Photrexa at no charge; and a prescription assistance program to minimize insured patients’ out-of-pocket expenses for Photrexa Viscous and Photrexa if their insurance plans deny coverage for the treatment. Avedro.com
POLAROID LAUNCHES INSTAGRAM CAMPAIGN
Safilo Group’s Polaroid Eyewear, for its spring summer 2017 collection, has launched an Instagram campaign that will be carried out simultaneously in seven countries, reaching more than 15 million users, as the brand celebrates its 80th anniversary. As part of the campaign, more than 250 Instagram ambassadors in the fashion and lifestyle segments will post on their Instagram accounts the creative contributions they have made, sharing it with their communities. You can follow the project in real time at #InstantExperience and #PolaroidSun.
ADVANCED VERSION OF B+L’S RENU
Bausch + Lomb has launched renu Advanced Formula multipurpose solution for soft and silicone hydrogel contact lenses. This new formula combines three disinfectants and two surfactants for lens cleaning and disinfection. The new renu Advanced Formula multipurpose solution will be the only renu solution on the market, replacing renu sensitive and renu fresh. Bausch.com/renuAdvancedFormula
First Insight Corp. announced that its MaximEyes software now integrates with GPN’s EDGE and EDGEPro data and metrics performance management software for optometry.
Eyefinity announced a formal partnership with Abyde, a technology start-up, to integrate Abyde’s HIPAA compliance management application into practice management and electronic health records software.
Opsis Therapeutics has formed a scientific advisory board to help develop and advance retinal cell therapies.
Heidelberg Engineering GmbH has acquired Medisoft Limited, a UK-based provider of electronic medical records software solutions.